Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The company plans to add 1700 beds by FY27 through the organic route
New leadership team announced at NATHEALTH Annual General Meeting 2024
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
Subscribe To Our Newsletter & Stay Updated
